A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia
Completed · Phase 3
Conditions studied: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
In brief
This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Key facts
- Study ID
- NCT03734016
- Run by
- BeiGene
- People needed
- 652
- Starts
- 2018-11-01
- Expected to finish
- 2024-02-28
- Last updated by the study team
- 2025-03-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- David Geffen School of Medicine At UCLA — Los Angeles, California, United States
- Rocky Mountain Cancer Centers Boulder — Boulder, Colorado, United States
- Scri Florida Cancer Specialists South — Fort Myers, Florida, United States
- Scri Florida Cancer Specialists North — St. Petersburg, Florida, United States
- Augusta University — Augusta, Georgia, United States
- Norton Cancer Institute Pavilion — Louisville, Kentucky, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Forrest General Hospital Cancer Center — Hattiesburg, Mississippi, United States
- Scri Hca Midwest Health — Kansas City, Missouri, United States
- Nebraska Medical Center — Omaha, Nebraska, United States
- Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
- Atlantic Health System — Morristown, New Jersey, United States
- Morristown Medical Center — Morristown, New Jersey, United States
- Columbia University Medical Center — New York, New York, United States
- Clinical Research Alliance, Inc — Westbury, New York, United States
- Duke University Hospital — Durham, North Carolina, United States
- Oregon Health and Science University — Portland, Oregon, United States
- Willamette Valley Cancer Center — Springfield, Oregon, United States
- Scri Tennessee Oncology Chattanooga — Chattanooga, Tennessee, United States
- Sarah Cannon Cancer Center — Nashville, Tennessee, United States
- Texas Oncology Fort Worth Cancer Center — Fort Worth, Texas, United States
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States
- Joe Arrington Cancer Research and Treatment Center — Lubbock, Texas, United States
- Texas Oncology San Antonio Medical Center Usor — San Antonio, Texas, United States
- Carti Cancer Center — Little Rock, Arkansas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.